FeesSafety
Pluang+

Natera and Tempus AI lead healthcare tech with strong growth but differ in risk and valuation for 2027.

Market News
19 Nov 2026, 21:20 WIB
The Motley Fool
View Source
Neutral
Natera and Tempus AI lead healthcare tech with strong growth but differ in risk and valuation for 2027.

Natera and Tempus AI are key players in healthcare technology, focusing on molecular diagnostics and AI-driven precision medicine. Natera leads with $2.9 billion revenue and strong cash flow, expanding through partnerships and clinical trials, though it faces risks from competition and patent issues. Tempus AI, with $1.5 billion revenue, leverages AI and large data for personalized care but has higher debt and regulatory risks. Both show rapid growth but differ in financial health and valuation, making them distinct choices for long-term investors in 2027.

Natera (NTRA) holds a market cap of $41.98 billion and an enterprise value of $41.12 billion, reflecting its strong position in the health sector. On Pluang, NTRA trades at USD 292.12 with a modest 1-day gain of 0.91% as of Nov 20, 2026, 02:31 WIB. In contrast, Tempus AI (TEM) has a market cap of $11.60 billion and an enterprise value of $12.40 billion, trading at USD 60.38 but down 5.09% in the last day, with a notably higher trading volume and a longer typical hold time of 25 days on Pluang. This data highlights the differing investor engagement and valuation scale between these two healthcare technology stocks.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App